BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 30, 2010
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 8/27 cls
Basilea Pharmaceutica AG (SIX:BSLN) Piper Jaffray Sam Fazeli Price target Overweight 0% CHF57
Fazeli lowered his target to CHF88 from CHF94 after the company reduced its 2010 net sales guidance for Toctino alitretinoin to CHF30M ($29M) from CHF35-45M ($33.9-$43.5M) due to pricing pressures in Europe, including a German rebate increase to 16% from 6% in August, and reimbursement delays. The vitamin A derived 9-cis retinoic acid...

Read the full 531 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >